Zivena
Company
Zivena develops one asset, in phase 3 (doxorubicin hydrochloride (liposomal) in breast cancer). Mostly small molecule acting on DNA damage response, apoptosis and TOP2B.
- 1
- Asset
- Furthest stage
- Phase 3
- 1
- Trial
- 11
- Signals
Pipeline
1doxorubicin hydrochloride (liposomal)
Topoisomerase II inhibitor and DNA intercalator formulated as an inhalation solution.
Phase 3, Small molecule, DNA damage response, Apoptosis, breast cancer, HIV infection
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms5
- Trials1
- Signals20
- Similar companies6